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STUDY PROTOCOL Open Access
Protocol for the adolescent hayfever trial: cluster
randomised controlled trial of an educational
intervention for healthcare professionals for the
management of school-age children with
hayfever
Victoria S Hammersley1*, Samantha Walker2, Rob Elton1, Aziz Sheikh1
Abstract
Background: Seasonal allergic rhinitis (hayfever) is common and can contribute to a considerable reduction in the
quality of life of adolescents. This study aims to examine the effectiveness of standardised allergy training for
healthcare professionals in improving disease-specific quality of life in adolescents with hayfever.
Methods/Design: Adolescents with a history of hayfever registered in general practices in Scotland and England
were invited to participate in a cluster randomised controlled trial. The unit of randomisation is general practices.
The educational intervention for healthcare professionals consists of a short standardised educational course, which
focuses on the management of allergic rhinitis. Patients in the intervention arm of this cluster randomised con-
trolled trial will have a clinic appointment with their healthcare professional who has attended the training course.
Patients in the control arm will have a clinic appointment with their healthcare professional and will receive usual
care.
The primary outcome measure is the change in the Rhinoconjunctivitis Quality of Life Questionnaire with Standar-
dised Activities (RQLQ(S)) score between baseline and six weeks post-intervention in the patient intervention and
control groups.
Secondary outcome measures relate to healthcare professionals’ understanding and confidence in managing aller-
gic rhinitis, changes in clinical practice, numbers of consultations for hayfever and adolescent exam performance.
A minimum of 11 practices in each arm of the trial (10 patients per cluster) will provide at least 80% power to
demonstrate a minimal clinically important difference of 0.5 in RQLQ(S) score at a significance level of 5% based on
an Intraclass Correlation Coefficient (ICC) of 0.02.
Discussion: At the time of submission, 24 general practices have been recruited (12 in each arm of the trial) and
the interventions have been delivered. Follow-up data collection is complete. 230 children consented to take part
in the trial; however complete primary outcome data are only available for 160. Further recruitment of general
practices and patients will therefore take place in the summer of 2010.
Trial Registration: Current Controlled Trials ISRCTN95538067
* Correspondence: vicky.hammersley@ed.ac.uk
1Allergy & Respiratory Research Group, Centre for Population Health
Sciences, The University of Edinburgh, Medical School, Teviot Place,
Edinburgh, EH8 9AG, UK
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Background
In the UK, allergic diseases have an overall lifetime pre-
valence of about 30% in the general population, with a
considerably higher prevalence in young people [1,2].
Intermittent allergic rhinitis (also known as seasonal
allergic rhinitis or hayfever) affects up to 30% of adults
and 40% of children at some time in their lives [2-5] Up
to 80% of patients with asthma also have allergic rhini-
tis, and nearly 40% of those with allergic rhinitis have
co-existing asthma [6,7]. Allergic rhinitis and its major
co-morbidity asthma cause significant health burdens to
the individual, and the impairment of quality of life
experienced by patients with rhinitis is at least as severe
as that of patients with asthma [8]. A recent editorial in
TheLancet reported that the economic burden posed by
allergic rhinitis has almost doubled since 2000 [9].
The Allergic Rhinitis in Asthma (ARIA) classification
scheme was introduced in 2001 and reinforced in 2008;
this subdivides allergic rhinitis into “intermittent” or
“persistent” disease [8,10]. Previously, allergic rhinitis
was subdivided based on time of exposure into “seaso-
nal” (more commonly known as hayfever), “perennial”
and “occupational” forms. Intermittent allergic rhinitis
(IAR) is defined as symptoms being present for less
than four days per week for less than four weeks and
persistent allergic rhinitis refers to symptoms that are
present for more than four days a week and for more
than four weeks. This new ARIA classification has not
yet been widely adopted in UK primary care, and
patients with IAR are thus still given a Read code [11]
for seasonal allergic rhinitis in their medical records and
hence these terms and codes need to be searched when
identifying local populations.
Common symptoms of allergic rhinitis include sneez-
ing, itching, watery rhinorrhoea and nasal blockage, and
these can have a considerable negative impact on chil-
dren in terms of their physical, social and psychological
well-being, and academic performance. Research has, for
example, shown that children with allergic rhinitis indi-
cated that they experienced particular problems with
their schoolwork [12], and a recent case control study of
teenage hayfever sufferers showed an association with
an increased risk of unexpectedly dropping a grade in
summer examinations (adjusted odds ratio 1.43; 95% CI
1.13-1.81) [13]. Children may also lose sleep, have
reduced ability to concentrate, and have a risk of devel-
oping a major depressive disorder [14]. The achievement
of optimal outcomes in children with allergic rhinitis
depends on timely diagnosis, followed by implementa-
tion of measures to reduce allergen exposure, selection
of safe and effective treatments and patient adherence
to therapeutic regimens. This can be facilitated by
appropriate training of healthcare professionals (HCPs)
and patients in the optimum treatment choices, timing
of medication commencement, appropriate techniques
to ensure appropriate delivery of intranasal treatments
and ensuring that compliance remains optimal.
Treatments for allergic rhinitis aim to minimise or
eliminate symptoms, optimise quality of life and reduce
the risk of developing co-morbidities. A report pub-
lished in 2003 Allergy - the unmet need, commissioned
by the Royal College of Physicians, clearly demonstrated
current deficiencies in allergy services in the UK, and
made a number of proposals to improve patient care,
both in primary-and secondary-care. These findings
have been confirmed in relation to allergic rhinitis in a
UK survey of general practitioners whose practice had a
self-declared interest in the management of allergic and
respiratory disorders [15], which found considerable var-
iation in their awareness and management of allergic
rhinitis. This again suggests that an educational inter-
vention covering all aspects of management of allergic
rhinitis in primary care is both timely and important.
The House of Lords Science and Technology Commit-
tee report on Allergy (2006-7) recommended that the
Department for Children, Families and Schools should
review the clinical care that children receive at school,
and should reassess the way they are supported through
the examination season [16]. However, the knowledge
and training in allergic diseases of teachers and support
staff may not be sufficient to support children though
this period. Enhancing the role of primary care profes-
sionals in ensuring control of allergy symptoms by
improving training and engaging the patient in self-care
may be a more beneficial and safer approach.
A multi-centre community based randomised con-
trolled trial showed that standardised allergy education
given to HCPs improved disease-specific quality of life
in patients with perennial rhinitis [17]. This study found
that a structured educational intervention was feasible
to deliver in primary care, was well received by GPs and
nurses, and improved outcomes in adults with perennial
rhinitis. The present trial is building on this by testing
the effectiveness of a modified version of this educa-
tional intervention in adolescents with hayfever.
Aims of the study
The primary aim of this study is to examine the effec-
tiveness of standardised allergy training in increasing
disease-specific quality of life of adolescents with hayf-
ever. A customised one-day short course, which focuses
on allergic rhinitis and its main co-morbidity asthma,
will be delivered to health care professionals.
The secondary aims are to examine whether attending
an allergic rhinitis and asthma short course can enhance
knowledge and skills of practitioners who consult with
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hayfever sufferers, changes in clinical practice, numbers
of consultation for hayfever and adolescent exam
performance.
Specific objectives
1. To evaluate the effectiveness of standardised allergy
training for HCPs on adolescent (12-18 years) rhinitis-
specific quality of life.
2. To examine the impact of improving symptoms of
hayfever on examination performance of adolescents.
3. To assess the change in allergy practice, improve-
ment in confidence and understanding, and manage-
ment of allergy symptoms of trained healthcare
professionals.
Methods/Design
Trial design
We are conducting a pragmatic cluster randomised trial.
Trial practices will receive either i) allergic rhinitis and
asthma management training with support materials
(rhinitis management algorithm and leaflet) or ii) sup-
port materials alone.
Eligibility of general practices for entering the trial
Inclusion criteria
• General practices within the recruitment areas of
the Scottish Primary Care Research Network
(SPCRN) and the Northern and Yorkshire Research
Network (NYREN).
• Practices that agreed to participate in the study
and were willing to allow healthcare professionals to
attend a one-day short course on allergic rhinitis
and asthma.
Exclusion criteria
• Practices not interested in participating and/or
unable to release practice staff to attend the training.
Eligibility of patients for entering the trial
All young people aged 12-18 years with hayfever were
eligible to participate. Hayfever was defined by the pre-
sence of a documented clinician diagnosis in the
patient’s health record and any evidence of treatment
used for allergic rhinitis. Patients were excluded if they
were unable to give consent or were taking part in any
other clinical trials involving treatments for allergic
rhinitis.
Recruitment
General practices and health care professionals
We applied to SPCRN and NYREN for their assistance
with practice recruitment. They wrote to general prac-
tices informing them of the study with an information
flyer. Additional contact was made with general prac-
tices in Scotland via NHS Education for Scotland (NES)
and local informal contacts. Where practices expressed
an interest in participating, an information sheet was
sent to each practice with the offer of a face-to-face or
telephone discussion at which the study was explained
in more details. A member of the practice team (Lead
GP or Practice Manager) then signed a consent form if
the practice decided to participate. Practices were asked
to nominate a member of their team who regularly sees
patients with hayfever, but who has not previously
received postgraduate allergy training. Twenty four gen-
eral practices were recruited.
Patient recruitment
In order to avoid the risk of allocation bias, practices
were asked to identify all eligible patients aged 12-18
years, through searches of the practice electronic medi-
cal record, prior to randomisation. Patients with a
recorded diagnosis of hayfever (Read code clinical terms
v2: H17), and/or evidence of use of hayfever medication
(oral antihistamines and topical steroids, drugs used in
nasal allergy and topical nasal decongestants; Read code
clinical terms v2: c8, c6, 18 and 19) were eligible to par-
ticipate. The practices were asked to write to eligible
participants sending an invitation letter with a partici-
pant information sheet, consent form and patient data
collection form for return directly to the study team.
Two versions of the consent form were used, one for
12-15 year old participants, which included a space for
parental/guardian consent, and one for 16-18 year old
participants. All recruitment materials were approved by
Lothian 2 Research Ethics Committee. Reminder invita-
tions were sent to non-responders by the practice nurse
two weeks after the initial mailing. Consenting patients
were asked to express their preferred method of com-
munication with the research team: email, text messages
or post.
Intervention
The intervention was in two phases: the first phase was
at the level of the practice/HCP and the second at the
level of the patient.
HCP training
Those practices randomly allocated to the intervention
arm were invited to nominate a HCP to attend an aller-
gic rhinitis and asthma short course run by Education
for Health. The short course was delivered by Education
for Health trainers; the programme for this course is
available in Additional file 1. Those practices rando-
mised to the control arm received written information.
Appointment with HCP (patients in both groups)
Once a patient had consented to take part in the trial by
returning the signed consent and data collection forms,
they were invited by email, text message or phone to
make an appointment with the nominated HCP by the
research team. The research team liaised with the
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general practice to ensure all consenting patients had
made an appointment during May-June 2009/10.
Patients were seen by the HCP in their usual clinic set-
ting. No guidance was given to either group about the
format of the consultation.
Allocation of trial interventions
The general practice was the unit of allocation. Rando-
misation to intervention or control was carried out
separately within each of the five participating regions:
Lothian; Borders; Durham and Tees Valley; Northum-
berland Tyne and Wear, York. For the four regions with
more than two practices, this was done using minimisa-
tion based on achieving optimum balance for practice
list size (three strata <5000, >5001, but <10000, >10000
patients currently registered) and deprivation score
(Index of Multiple Deprivation), according to the meth-
ods described by Carter and Hood [18]
The reason for randomisation by centre was to help
ensure an even distribution of intervention and control
practices as there is likely to be a geographical variation
in pollen counts between centres.
Outcome measures
Primary outcome
• The change in the RQLQ(S) score between base-
line and 6 weeks post-intervention in the interven-
tion and control groups.
The RQLQ(S) measures the problems experienced by
young people with hayfever. This is a validated and
widely used tool in clinical trials [12,17,19,20]. It has
been designed to ask patients about seven domains:
activity; sleep; non-nose/eye symptoms; practical pro-
blems; nasal symptoms; eye symptoms; and emotional
function.
Quality of life using the validated RQLQ(S) was mea-
sured at the beginning of the hayfever season (March
2009) prior to the HCP clinic appointment, and
repeated at six weeks post-intervention.
Secondary outcomes
• Weekly pollen count data collected over the dura-
tion of trial.
Clinical outcomes
• Patient reported symptom scores using a visual
analogue scale.
• Overall assessment of hayfever symptoms com-
pared with the previous season.
• Number of general practitioner and practice nurse
consultations for hayfever, prescribed (from clinical
records) and over-the-counter (from patients) medi-
cation data were collected.
Educational outcomes
Educational data will be collected via the Local Educa-
tion Authority. This will be based on final grades for the
age-specific assessment adjusted for pre-trial grades,
where possible.
Process outcomes: assessment of change in clinical practice
These were measured using a questionnaire assessing
change in allergy practice and improvement in confi-
dence, understanding and management of allergic symp-
toms. All HCPs in the intervention arm were asked to
complete this questionnaire immediately before and
after the training, and after seeing their last patient in
the trial.
Sample size
There is little published literature about the likely design
effect size in healthcare interventions and hayfever qual-
ity of life, however using data from a previous parallel
group study using the RQLQ in adults with perennial
rhinitis [17], a mixed-model analysis of variance gave an
F-ratio of less than unity, indicating that there was less
variation between practices than would be expected by
chance (data available on request). This means that the
inter-practice variance and hence the ICC is estimated
as zero, and there would thus be no anticipated design
effect for the proposed cluster randomised trial. There
are however obvious differences between the study in
adults and this cluster trial in adolescents, including the
trial design; estimates of the between-practice variation
in the proposed study and its effect on sample size are
shown in Table 1.
Sampsize [21] was used for sample size calculations.
A cluster size of 10 was chosen as pilot work suggested
that it should be possible to recruit at least this number
of adolescents with diagnosed current hayfever from
most general practices (data available on request).
Taking account of the cluster design, using a standard
deviation of 1.2 [20] with a power of 80% to detect a
minimal clinically important difference of 0.5 in RQLQ
(S) score at a significance level of 5%, an estimate of the
cluster size of 10 and an ICC of 0.02 required a total of
22 clusters and an adjusted sample size of 220 patients
(unadjusted 180).
Based on these figures, we aimed to recruit at least
22 practices, inflated by 20% to account for possible
Table 1 Number of patients needed with varying ICCs
ICC Cluster size No. of clusters No. of patients
0.01 10 20 200
0.02 10 22 220
0.05 10 24 240
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losses to follow-up, resulting in 22 clusters (practices)
recruiting 12 patients per practice, giving a total of
264 patients in the study (i.e. 132 per arm).
With these numbers, the study is sufficiently powered
for the primary outcome measure; it is however likely
to be underpowered for the secondary educational
outcomes based on examination data [13].
Compliance
All practices were given clear written information on what
the study involved and were visited by the researcher prior
to agreeing to take part in the study. In order to maximise
the opportunities for intervention HCPs to attend the
training, the course was run twice on separate dates in
two different venues; all intervention HCPs attended a
training day. The researcher assisted the practice with the
mailings and reminders to eligible patients, and a clear
account of payment for all practice time was given to the
practices at the beginning, which included administrative
time and backfill for the HCPs attending the training. The
control group practices were offered the same short course
at the end of the study and this was attended by nine out
of the 12 control practices.
Withdrawal of patients from the study
There were three points at which consenting patients
could withdraw from the study:
i) prior to completing baseline questionnaires
ii) prior to attending the practice nurse appointment
iii) prior to completing the six weeks post-intervention
questionnaires.
Statistical analysis
Data analysis, using the following analysis plan, will be
undertaken blind to the allocation arm. The primary
analysis will be a per protocol analysis on complete
cases only. An intention-to-treat analysis using the last
observation carried forward is not feasible since imput-
ing of the baseline data (which were collected before the
pollen season) for subjects whose final RQLQ(S) is miss-
ing would not be a conservative assumption. This is
because the lack of change from a value measured
before the hayfever season might be better than
expected. (i.e. baseline values may be low on a scale of
0-6 where 0 is not troubled and 6 is extremely troubled,
and imputing these data for an RQLQ measured at the
peak of the season, which may have been high might
result in over-estimation of the intervention effect if
more cases had missing data in the intervention group.)
Descriptive analyses
Describing baseline characteristics of patients and practices
a) For each treatment arm, we will describe:
i) Patient age (mean and SD) and sex (number and
percentage)
ii) Practice list size (median and IQR, or mean and
SD if normally distributed)
iii) Practice population by age group (number and
percentage)
iv) Practice deprivation (IMD or proxy measure)
v) Whole time equivalent GPs and practice nurses
per practice (median and IQR, or mean and SD if
normally distributed).
Comparison between treatment arms
The difference in the validated RQLQ(S) score between
the intervention and control groups at baseline and six
weeks post-intervention will be compared.
Adjusting for
1. Practice level stratum (region, list size and IMD or
proxy) and baseline RQLQ(S).
2. Practice level stratum (region, list size and IMD or
proxy). This will potentially be a more powerful
comparison in the event that substantial numbers of
subjects provide follow-up data, but not baseline
data.
Multi-level modelling using a random-effects model
will be used to take account of between and within clus-
ter variation, adjusting for strata and individual covari-
ates for example pre-intervention level of RQLQ(S).
Estimates and standards errors of the intervention
effects will be reported and normal chi-square tests on
the ratio of these estimates to their standard errors will
be used. An estimate and confidence intervals for the
ICC will be calculated, adjusting for baseline RQLQ(S).
Analysis will be undertaken using MLwiN.
Missing data
RQLQ(S)
The RQLQ(S) is divided into seven domains, with vary-
ing numbers of questions per domain, and the overall
RQLQ(S) score is calculated from the mean of each
domain. Where responses to a whole domain within the
RQLQ(S) are missing, this patient will be excluded from
the analysis.
Reporting and dissemination
Reporting will adhere to revised CONSORT criteria for
cluster trials [22,23].
Trial Steering Committee
The Trial Steering Committee (TSC) will monitor and
supervise the trial and comment on any proposed
amendments to the protocol. The TSC is chaired by
Professor Anthony Avery and Dr Glenis Scadding, Dr
Sarah Rodgers and Dr Sarah Armstrong are the other
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external members of the committee. The TSC has
agreed to operate within the framework suggested in the
MRC Guidelines for good clinical practice in clinical
trials [24].
Ethical considerations
The clinical trial will be conducted according to the
Helsinki Declaration [25], Good Clinical Practice Guide-
lines [24] and NHS research governance requirements.
Patients who have agreed to allow the study team to
access their clinical and educational records have pro-
vided written informed consent. All patients were made
aware that that can withdraw from the research at any
time. The study has been approved by Lothian 2
Research Ethics Committee (Reference 08/S1102/37).
All appropriate NHS Research and Development
approvals have been obtained.
Study timeline
Trial Start: 1 August 2008
Baseline data collection: March 2009 and 2010
Interventions in general practice: April 2009 and 2010
(training), May/June 2009 and 2010 (patient appoint-
ments with HCPs)
End of interventions in general practice: June 2009
and 2010
End of 6 week follow-up: August 2009 and 2010
Start of data analysis: September 2010
Planned study end date: December 2010
Duration: 29 months
Current study status
At the time of submission, outcome data has only been
obtained for 160 patients from 24 general practices,
leading to lower power than was originally intended for
the study, and further recruitment is therefore planned
in the summer of 2010. It is planned to recruit a further
10 practices, which will achieve the original target of
220 patients if cluster sizes are similar to those for 2009.
We calculate that this will give similar power to that
originally planned, because the gain in power from hav-
ing more clusters of smaller size will be counterbalanced
by some loss of power from the fact that there was sub-
stantial variation in the sizes of the different clusters.
Additional material
Additional file 1: Programme for the Essential Asthma and Allergic
Rhinitis Short Course.
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